HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles

Alhareth, Khair; Vauthier, Christine; Gueutin, Claire; Ponchel, Gilles; Moussa, Fathi

doi:10.1016/j.jchromb.2012.01.025

Cited by 61 publications

(32 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quantification of doxorubicin was performed using daunorubicin (Dau, Sigma) as an internal standard 26 . Briefly, tissues were homogenized in PBS (100 mg tissue/330 mL PBS), and then mixed with 10 µL Dau (50 µg/mL).…”

Section: Methodsmentioning

confidence: 99%

An injectable nanoparticle generator enhances delivery of cancer therapeutics

et al. 2016

View full text Add to dashboard Cite

The efficacy of cancer drugs is often limited because only a small fraction of the administered dose accumulates in tumors. Here we report an injectable nanoparticle generator (iNPG) that overcomes multiple biological barriers to cancer drug delivery. The iNPG is a discoidal micrometer-sized particle that can be loaded with chemotherapeutics. We conjugate doxorubicin to poly(L-glutamic acid) via a pH-sensitive cleavable linker, and load the polymeric drug (pDox) into iNPG to assemble iNPG-pDox. Once released from iNPG, pDox spontaneously forms nanometer-sized particles in aqueous solution. Intravenously injected iNPG-pDox accumulates at tumors due to natural tropism and enhanced vascular dynamics and releases pDox nanoparticles that are internalized by tumor cells. Intracellularly, pDox nanoparticles are transported to the perinuclear region and cleaved into Dox, thereby avoiding excretion by drug efflux pumps. Compared to its individual components or current therapeutic formulations, iNPG-pDox shows enhanced efficacy in MDA-MB-231 and 4T1 mouse models of metastatic breast cancer, including functional cures in 40–50% of treated mice.

show abstract

Section: Methodsmentioning

confidence: 99%

An injectable nanoparticle generator enhances delivery of cancer therapeutics

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Thus, method sensitivity was drastically improved. 320 lower than 0.01 ng mL −1 and 0.1 ng mL −1 were obtained, respectively, for the LC-MS analysis of anthracyclines in urine treated by SPE. 335 LC-LIF-MS was also developed for studying in vitro metabolism of doxorubicin: quantification was performed on the results obtained with LIF detection (LOD ∼ 1 µg mL −1 ) and metabolites identification was performed with MS detection.…”

Section: Intercalating Agentsmentioning

confidence: 82%

Antineoplastic drugs and their analysis: a state of the art review

Guichard

Guillarme

Bonnabry

et al. 2017

Analyst

View full text Add to dashboard Cite

The number of patients suffering from cancer is constantly increasing and, consequently, the number of different chemotherapy treatments administered is increasing. Given the high reactivity and toxicity of antineoplastic drugs, analytical methods are required in all pharmaceutical fields, from drug development to their elimination in wastewater; including formulation quality control, environment and human exposure and therapeutic drug monitoring. The aim of this paper is to provide an overview of the analytical methods available for the determination of antineoplastic drugs in different matrices such as pharmaceutical formulations, biological and environmental samples. The applicability and performance of the reported methods will be critically discussed, with focus on the most commonly used antineoplastic drugs. Only conventional compounds and small molecules for targeted therapy will be considered in the present review.

show abstract

“…The regression equation for the plasma samples was y = 0.1728 x + 0.0540 ( R 2 = 0.9953) and that for the liver samples was y = 0.1932 x + 0.0210 ( R 2 = 0.9975). Because the slopes and the intercepts of the tissue calibration curves did not vary significantly and the recoveries of DOX from the QC samples also did not differ significantly, we used the calibration curves obtained from the spiked QC liver samples to quantify DOX in all tissues [11]. …”

Section: Resultsmentioning

confidence: 99%

Deposition of Doxorubicin in Rats following Administration of Three Newly Synthesized Doxorubicin Conjugates

Huan

Tian

Han

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

We previously reported the synthesis of three DOX conjugates that represented different targeting vehicles and showed them to have antitumor activity both in vitro and in vivo. However, the relationships between the pharmacokinetics of these DOX conjugates and their chemical structures were not characterized. In the current study, free DOX derived from each of the conjugates was found at low levels in the rat circulatory system, with conjugated DOX being the major form. The two polyethylene glycol (PEG) conjugates slowly released DOX, and t 1/2 β for total DOX from DOX-LNA, PEG-ami-DOX, and PEG-hyd-DOX was 5.79, 10.22, and 15.18 h, respectively. All three conjugates also deposited less DOX into normal organs than did an equivalent dose of free DOX, and the Cmax value of free DOX released by DOX- LNA, PEG-ami-DOX, and PEG-hyd-DOX was 32.5, 9.5, and 4.7 μg/g, respectively. Among the conjugates, the compound with an acid-labile bond between PEG and DOX exhibited the lowest free DOX deposition in healthy tissues, which should decrease the systemic toxicity of free DOX while allowing for tumor targeting by PEG.

show abstract

HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles

Cited by 61 publications

References 29 publications

An injectable nanoparticle generator enhances delivery of cancer therapeutics

An injectable nanoparticle generator enhances delivery of cancer therapeutics

Antineoplastic drugs and their analysis: a state of the art review

Deposition of Doxorubicin in Rats following Administration of Three Newly Synthesized Doxorubicin Conjugates

Contact Info

Product

Resources

About